Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CERO THERAPEUTICS HOLDINGS, INC. Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.	United States of America	CERO
CervoMed Inc. Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.	United States of America	CRVO
Cessatech A/S Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.	Denmark	CESSA
CG Invites Co., Ltd. Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.	South Korea	083790
CG Oncology, Inc. Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.	United States of America	CGON
CHA Vaccine Research Institute Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.	South Korea	261780
CHEIL BIO CO., LTD. Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.	South Korea	052670
Chemical Works of Gedeon Richter Plc Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.	Hungary	RICHT
Chemomab Therapeutics Ltd. Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.	United States of America	CMMB
CHINA PHARMA HOLDINGS, INC. Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.	United States of America	CPHI